Genentech, MedImmune end patent rift over Synagis

06/11/2008 | Bloomberg Businessweek · TheStreet.com

Genentech and MedImmune have reached an agreement to resolve a patent dispute over motavizumab and Synagis, a respiratory drug. The settlement allows MedImmune -- a unit of AstraZeneca PLC -- to receive licenses for selected pipeline products under a patent Genentech co-owns with City of Hope National Medical Center.

View Full Article in:

Bloomberg Businessweek · TheStreet.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations